Clinical Trials are the Backbone of the Consortium


Currently enrolling trials

UCHMC1401: A Phase II Study of Punctual, Cyclic, and Intensive Chemotherapy with Liposomal Cytarabine (Depocyt®) CNS Prophylaxis for Adults With Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

o   Participating Centers: UCSD (Primary), UCLA, UCSF, UCD

o   https://clinicaltrials.gov/ct2/show/NCT02043587?term=Depocyt&rank=7

 

UCHMC1502: A Phase I/II Study of PiC-D (Ixazomib in Combination with Pomalidomide, Clarithromycin and Dexamethasone) in Patients with Double Refractory Multiple Myeloma

o   Participating Centers: UCD (Primary), UCSD, UCI

o   https://clinicaltrials.gov/ct2/show/NCT02542657?term=Tuscano&rank=4

 

·UCHMC1504: A Phase I/II study of blinatumomab in combination with pembrolizumab (MK-3475) for adults with relapsed or refractory B-lineage acute lymphoblastic leukemiawith high bone marrow lymphoblast count: A University of California Hematologic Malignancies Consortium

o   Participating Centers: UCSD (Primary), UCI, UCSF

o   https://clinicaltrials.gov/ct2/show/NCT03160079?term=wieduwilt&draw=1&rank=1

 

  • UCHMC1607: A Phase Ib Dose Escalation Trial of Carfilzomib in Combination with Bendamustine and Rituximab In Patients with Relapsed or Refractory non-Hodgkin Lymphoma

o   Participating Centers: UCSF (Primary), UCSD, UCD

o   https://clinicaltrials.gov/ct2/show/NCT02187133?term=andreadis&draw=1&rank=4

 •UCHMC1809: Phase II study of the combination of daratumumab, ixazomib, pomalidomide, and dexamethasone as salvage therapy in relapsed/refractory multiple myeloma (A University of California Hematologic Malignancies Consortium Protocol) (Costello, UCSD)

  • Participating Centers: UCSD, UCSF, UCLA, UCD, UCI

  • NCT#: NCT03590652

 

Completed Trials  

·UCHMC1503: Phase 1b Trial of the Combination of Ibrutinib and Azacitidine for the Treatment of Higher Risk Myelodysplastic Syndromes in Previously Treated Patients or in Untreated Patients Unfit for or Who Refuse Intense Therapy(UCDCC#256 [PCYC#20051])

o   Participating Centers: UCD (Primary), UCSD, UCSF

o   https://clinicaltrials.gov/ct2/show/NCT02553941?term=brian+jonas&rank=2

Future Trials

UCHMC1811: CPX-351 PLUS ENASIDENIB FOR RELAPSED ACUTE MYELOGENOUS LEUKEMIA CHARACTERIZED BY THE IDH2 MUTATION (Oliai/Schiller, UCLA)

–Participating sites: UCLA, UCSD, UCD, UCSF

UCHMC1812:A PHASE IB TRAIL WITH DOSE EXPANSION EVALUATING CPX-351 PLUS GEMTUZUMAB OZOGAMICIN FOR RELAPSED ACUTE MYELOGENOUS LEUKEMIA (Oliai/Schiller, UCLA)

–Participating sites: UCLA, UCSD, UCD, UCSF, UCI

UCHMC1913: Phase II study of the combination of glasdegib and Vyxeos (CPX-351) in previously untreated patients with Acute Myelogenous Leukemia with MDS related changes or Acute myeloid leukemia evolving out of MDS (Jeyakumar, UCI)

–Participating Sites- Pending

UCHMC1914: Phase II, single-arm, open-label clinical study of fludarabine in combination with CPX-351 for adults with newly-diagnosed acute myeloid : A University of California Hematologic Malignancies Consortium Protocol (UCHMC1914) (Schwartz/Wieduwilt, UCSD)

–Participating Sites- Pending